Drugs / Oral cholera vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT06455852 | Mar 2025 → Dec 2028 expected | cholera | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01981616 Background | Sep 2011 → May 2012 | inflammatory bowel disease | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oral cholera vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455852 ↗ |
| Known as | OCV | “some individuals who receive inactivated oral cholera vaccine (OCV) will develop antibody responses which predict protection against V. cholerae infection” NCT06455852 ↗ |
| Modality | Vaccine | “Oral cholera vaccine” NCT01981616 ↗ |
| Route | Oral | “Oral cholera vaccine” NCT01981616 ↗ |